REGIONAL HEALTH PROPERTIES, INC financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data REGIONAL HEALTH PROPERTIES, INC files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	27.6	25.1	22	20.1	17.6	26.7	35.9	17.2	18.3	53.2
Cost of revenue										6.98
Gross profit										46.2
General and administrative	7.71	3.85	3.69	3.19	3.37	3.93	4.65	5.41	5.41	12
Operating expenses	23.1	20	22.8	14.7	15.3	24.2	42.7	18	18.2	54.2
Operating income	4.52	5.14	-0.79	5.46	2.29	2.53	-6.82	-0.82	0.16	1.66
Interest expense	7.15	4.1	5.93	5.27	2.78	2.67	2.53	2.75	2.71	2.67
Other non-operating income	1.28	-4.63	-11.2	-0.59	-2.9	-3.72	-0.05	-3.07	-3.38	1.71
Pre-tax income	5.8	0.51	-12	4.87	-0.6	-1.14
Income tax	-0.16	-0.19	-0.04	0						0.11
Net income to minority interests	0
Net income	-7.46	-0.99	-11.9	5.5	-0.69	-1.18	-6.87	-3.89	-3.22	3.05
EBITDA	9.82	10	3.84	8.9	5.19	5.12	-4.42	1.43	2.22	3.73
EPS, basic	-0.74	-5.20	-11.86	-2.07	-5.74	-5.87	-8.93	21.05	-1.73	1.09
EPS, diluted	-0.74	-5.20	-11.86	-2.07	-5.74	-5.87	-8.93	21.05	-1.73	1.09
Shares, basic (weighted)	19.9	1.65	1.68	1.69	1.69	1.73	1.78	0	0	0
Shares, diluted (weighted)	19.9	1.65	1.68	1.69	1.69	1.73	1.78	0	0	0
Dividend per share	0.17

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	14	1.82	2.4	4.4	4.2	6.8	0.8	1	0.58	3
Receivables	2.43	0.95	1	1	2.1	2.15	6.29	1.4	3.36	8.03
Inventory										1.35
Other current assets	2.4	0.3	0.5	0.2	0.3	0.5	0.7	0.6	0.63	1.62
Total current assets	20.5	4.7	8.08	7.4					6.82	16.3
Property, plant and equipment	79.2	81.2	77.2	54.7	52.5	50.1	46.6	34.7	33.5	35.8
Lease right-of-use assets			41	37.3	33.7	29.9	2.85	2.56	2.15
Goodwill	2.11	2.11	2.11	1.59	1.59	1.59	1.59	1.59	1.59	1.59
Intangible assets	24.6	23.3	21.3	13.9	13.2	12.7	12.3	11.8	11.4	10.8
Other non-current assets	0.51	0.54	0.07						4.68	3.84
Total assets	119	107	101	114	108	106	68.6	62.2	60.5	67.8
Accounts payable	3.04	4.39	4.36						3.7	6.99
Accrued liabilities	9.08								5.41	7.89
Short-term debt	13.2	8.1	26.4						2.2	5.41
Total current liabilities	25.3	19.5	36.7	14.1					20.4	24.2
Long-term debt	66.8	65	81.3	55.4	54.4	52.9	52.2	50.7	39.3	34.7
Lease liabilities									1.98	2.33
Other non-current liabilities	3.68	4.13	2.79						1.71	1.55
Total liabilities	96	88.7	94.4	102	96.9	95.3	64.9	62	63.4	62.8
Total debt	80	73.1	81.3	55.4	54.4	52.9	52.2	50.7	49.7	43.2
Paid-in capital	61.6	61.7	61.9	62	62	62.5	62.7	63.1	63.2	67.3
Retained earnings	-99.6	-106	-118	-113	-113	-115	-121	-81.9	-85.1	-81.8
Other comprehensive income										0.02
Shareholders' equity	-37.9	17.9	6.15	11.7	11.1	10.4	3.72	0.19	-2.92	0.35
Total equity	-37.9	17.9	6.15	11.7	11.1	10.4	3.72	0.19	-2.92	0.35
Total liabilities and equity	119	107	101	114	108	106	68.6	62.2	60.5	67.8
Shares outstanding	19.9	1.65	1.69	1.69	1.69	1.78	1.78	1.84	1.88	3.94

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-7.46	-0.99	-11.9	5.5	-0.69	-1.18	-6.87	-3.89	-3.22	3.37
Depreciation and amortization	5.3	4.87	4.63	3.44	2.89	2.59	2.4	2.26	2.06	2.06
Stock-based compensation	1.13	0.27	0.18	0.09	0.05	0.48	0.23	0.36	0.11	0.23
Deferred income tax	-0.16	-0.19	-0.04	0
Change in receivables	-0.55	0.18	-0.5	0.47	-1.08	0.79	-6.68	3.55	-1.72	-3.61
Change in inventory										-0.04
Change in payables	-1.36		1.24	-0.34	0.01	3.38	-0.39	-1.78	2.56	2.95
Cash from operations	-3.41	5.15	1.35	2.4	1.3	4.89	-3.6	3.71	1.94	-2.26
Capital expenditures	-1.5	-0.85	-0.34	-0.06	-0.45	-0.12	-0.28	-0.96	-0.53	-0.87
Cash from investing	24.1	-2.27	-0.34	3.82	-0.45	-0.12	-0.28	-0.96	-0.53	15.1
Debt issued			2.4		0.23		7.78
Debt repaid						-2.27	-8.83	-1.36	-1.4	-1.79
Stock issued										0.13
Share buybacks	-0.52	-0.19				-0.01	-0.05
Dividends paid	0
Cash from financing	-9.4	-17	0.12	-4.67	-1.39	-2.42	-2.06	-2.48	-2.13	-10.3
Net change in cash	11.3	-14.2	1.13	1.55	-0.55	2.36	-5.94	0.28	-0.71	2.59
Free cash flow	-4.91	4.3	1.01	2.34	0.85	4.77	-3.88	2.75	1.41	-3.13
Interest paid	6.13	3.78	5.22	4.81	2.45	2.8	2.45	2.67	2.65	2.53
Income taxes paid	0	0.03

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.07 on September 28, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	78.5%	Gross profit / revenue.
Operating margin	1.9%	Operating income / revenue.
EBITDA margin	5.3%	EBITDA (operating income + depreciation and amortization) / revenue.
Net margin	5.4%	Net income / revenue.
FCF margin	-4.8%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	-3.2%	Cash from operations / revenue.
Return on assets (ROA)	6.5%	Net income / average total assets.
Return on invested capital (ROIC)	3.2%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Stock-based pay / revenue	0.4%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	1.7%	Capital expenditures / revenue.
D&A / revenue	3.4%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	189.9%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	14.0%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	24.8%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y	933.5%	Operating income vs the same period a year earlier. Only from a positive base.
Operating income CAGR, 5y	-6.2%	Compound annual growth of operating income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EBITDA growth, 1y	67.7%	EBITDA vs the same period a year earlier. Only from a positive base.
EBITDA CAGR, 5y	-6.4%	Compound annual growth of ebitda over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y	-216.3%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow growth, 1y	-321.4%	Free cash flow vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	-54.5%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	-49.9%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	12.1%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-0.4%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-8.9%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	51.0%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	-88.4%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	-72.2%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	0.65x	Current assets / current liabilities.
Quick ratio	0.44x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.06x	(Cash + short-term investments) / current liabilities.
Debt / assets	62.6%	Total debt / total assets.
Liabilities / assets	95.6%	Total liabilities / total assets.
Net debt	$40.9M	Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA	9.48x	Net debt / EBITDA (twelve months), when EBITDA is positive.
Interest coverage	0.63x	Operating income / interest expense.
Working capital	-$9.4M	Current assets - current liabilities.
Goodwill and intangibles / assets	17.9%	(Goodwill + intangible assets) / total assets.
Tangible book value	-$13.9M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	1.20x	Revenue / average total assets.
Fixed asset turnover	2.32x	Revenue / average property, plant and equipment.
Inventory turnover	11.6x	Cost of revenue / average inventory.
Days inventory	32 days	365 x average inventory / cost of revenue.
Receivables turnover	7.92x	Revenue / average receivables.
Days sales outstanding	46 days	365 x average receivables / revenue.
Days payables	152 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	-75 days	Days inventory + days sales outstanding - days payables.
FCF conversion	-89.1%	Free cash flow / net income, when net income is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$1.13	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$20.75	Revenue / diluted weighted shares.
FCF per share	-$1.00	Free cash flow / diluted weighted shares.
Operating cash flow per share	-$0.65	Cash from operations / diluted weighted shares.
Book value per share	-$0.44	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	-$3.54	Tangible book value / shares outstanding.
Cash per share	$0.43	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$4.2M	Share price x shares outstanding.
Enterprise value	$45.1M	Market cap + total debt - cash - short-term investments.
P/E	0.95x	Market cap / net income. Only when net income is positive.
P/S	0.05x	Market cap / revenue.
EV/Sales	0.55x	Enterprise value / revenue.
EV/EBIT	28.7x	Enterprise value / operating income, when both are positive.
EV/EBITDA	10.5x	Enterprise value / EBITDA, when both are positive.
FCF yield	-93.8%	Free cash flow / market cap.
Earnings yield	105.3%	Net income / market cap (the inverse of P/E).

What was REGIONAL HEALTH PROPERTIES, INC's revenue in fiscal 2025?

REGIONAL HEALTH PROPERTIES, INC reported revenue of $53.2M for fiscal 2025, 189.9% higher than the year before.

Was REGIONAL HEALTH PROPERTIES, INC profitable in fiscal 2025?

Yes. Net income was $3.0M, a net margin of 5.7%.

How much free cash flow did REGIONAL HEALTH PROPERTIES, INC generate in fiscal 2025?

Cash from operations of $2.3M minus capital expenditures of $869.0K left free cash flow of -$3.1M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to REGIONAL HEALTH PROPERTIES, INC